atrial fibrillation

81 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise fo

Section: CardiologyOct 9, 2025

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

atrial fibrillation

Latest news

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation

Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

Dynamic Triglyceride-Glucose Index Trajectories as Predictors of Mortality in Critically Ill Patients with Atrial Fibrillation

Dynamic Triglyceride-Glucose Index Trajectories Predict Mortality in Critically Ill Atrial Fibrillation Patients

Optimizing Anticoagulant Therapy in Frail Elderly AF Patients: Insights from the COMBINE-AF Substudy

Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

OPTIMAS Trial: Early vs. Delayed Anticoagulation in Acute Ischemic Stroke with Atrial Fibrillation and Chronic Kidney Disease

Balancing Stroke Prevention and Bleeding Risk: Timing of DOAC Restart After Serious Bleeding in Atrial Fibrillation